ATX-LPA receptor axis in inflammation and cancer

Cell Cycle

Volumn 8, Issue 22, 2009, Pages 3695-3701

  Liu, Shuying ^a   Murph, Mandi ^b   Panupinthu, Nattapon ^a   Mills, Gordon B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

ATX; Breast cancer; Cytokines; G protein coupled receptor; Inflammation; LPA; Target therapy

Indexed keywords

AUTOTAXIN; ESTROGEN RECEPTOR; LPATHOMAB; LYSOPHOSPHATIDIC ACID RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; SPHINGOMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BLASTOCYST; BREAST CANCER; BREAST CARCINOGENESIS; BREAST METASTASIS; BREAST TUMOR; CALCIUM CELL LEVEL; CANCER INVASION; CELL STIMULATION; CELL TYPE; CLINICAL RESEARCH; CLINICAL TRIAL; CRANIOFACIAL MALFORMATION; GENE OVEREXPRESSION; HETEROZYGOTE; HIGH THROUGHPUT SCREENING; HUMAN; MASTITIS; NONHUMAN; OVARY CANCER; PROTEIN FAMILY; REVIEW; SUCKLING; TRANSACTIVATION; UTERUS CONTRACTION; VALIDATION STUDY;

MUS MUSCULUS;

EID: 70449769732     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.22.9937     Document Type: Review

References (116)

1. Tokumura A. A family of phospholipid autacoids: occurrence, metabolism and bioactions, Prog. Lipid Res 1995; 34:151-184
2. Hecht JH, Weiner JA, Post SR, Chun J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Biol Chem 1996; 135:1071-1083 (Pubitemid 26403779)
3. An S, Bleu T, Hallmark OG, Goetzl EJ. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem 1998; 273:7906-7910
4. Bandoh K, Hosono H, Kobayashi S, Kobayashi T, Murakami-Murofushi K, et al. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem 1999; 274:27776-27785 (Pubitemid 129527831)
5. 9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 2003; 278:25600-25606
6. q-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 2006; 281:23589-23597
7. 6. J Biol Chem 2009; 284:17731-17741
8. McIntyre TM, Pontsler AV, Silva AR, St. Hilaire A, Xu Y, Hinshaw JC, et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist. Proc Natl Acad Sci USA 2003; 100:131-136 (Pubitemid 36078041)
9. Tabata K, Baba K, Shiraishi A, Ito M, Fujita N. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun 2007; 363:861-866 (Pubitemid 47516713)
10. Murakami M, Shiraishi A, Tabata K, Fujita N. Identification of the orphan GPCR, P2Y10 receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem Biophys Res Commun 2008; 371:707-712
11. Sabbadini RA. Targeting sphingosine-1-phosphate for cancer therapy. Br J Cancer 2006; 95:1131-1135
12. Okita M, Gaudette DC, Mills GB, Holub BJ. Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine (lysoPC) in ovarian cancer patients. Int J Cancer 1997; 71:31-34 (Pubitemid 27158406)
13. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Biol Chem 2002; 158:227-233
14. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradere JP, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 2006; 26:5015-5022 (Pubitemid 43955815)
15. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 2006; 281:25822-25830 (Pubitemid 44401970)
16. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nature reviews 2003; 3:582-591 (Pubitemid 37328830)
17. Zhang XF, Schaefer AW, Burnette DT, Schoonderwoert VT, Forscher P. Rho-dependent contractile responses in the neuronal growth cone are independent of classical peripheral retrograde actin flow. Neuron 2003; 40:931-944 (Pubitemid 37522051)
18. A1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc Natl Acad Sci USA 2000; 97:13384-13389
19. 2. Mol Cell Biol 2002; 22:6921-6929
20. Ye X, Hama K, Contos JJ, Anliker B, Inoue A, Skinner MK, et al. LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing. Nature 2005; 435:104-108 (Pubitemid 40655916)
21. Lin S, Wang D, Iyer S, Ghaleb AM, Shim H, Yang VW, et al. The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology 2009; 136:1711-1720
22. Hojilla CV, Wood GA, Khokha R. Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res 2008; 10:205.
23. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005; 7:411-423
24. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nature reviews 2004; 4:71-78
25. Cummings R, Zhao Y, Jacoby D, Spannhake EW, Ohba M, Garcia JG, et al. Protein kinase Cδ mediates lysophosphatidic acid-induced NFκB activation and interleukin-8 secretion in human bronchial epithelial cells. J Biol Chem 2004; 279:41085-41094 (Pubitemid 39287710)
26. Zhao Y, He D, Saatian B, Watkins T, Spannhake EW, Pyne NJ, et al. Regulation of lysophosphatidic acid-induced epidermal growth factor receptor transactivation and interleukin-8 secretion in human bronchial epithelial cells by protein kinase Cδ, Lyn kinase and matrix metalloproteinases. J Biol Chem 2006; 281:19501-19511 (Pubitemid 44035454)
27. Saatian B, Zhao Y, He D, Georas SN, Watkins T, Spannhake EW, et al. Transcriptional regulation of lysophosphatidic acid-induced interleukin-8 expression and secretion by p38 MAPK and JNK in human bronchial epithelial cells. Biochem J 2006; 393:657-668 (Pubitemid 43168213)
28. 2 release via C/EBPβ in human bronchial epithelial cells. Biochem J 2008; 412:153-162
29. Barekzi E, Roman J, Hise K, Georas S, Steinke JW. Lysophosphatidic acid stimulates inflammatory cascade in airway epithelial cells. Prostaglandins Leukot Essent Fatty Acids 2006; 74:357-363 (Pubitemid 43816848)
30. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang W, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion and metastases. Cancer Cell 2009; 15:539-550
31. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, et al. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 2008; 100:1630-1642
32. Kang YC, Kim KM, Lee KS, Namkoong S, Lee SJ, Han JA, et al. p38 MAPK: critical molecule in thrombin-induced NFkappaB-dependent leukocyte recruitment. Am J Physiol Heart Circ Physiol 2002; 284:1095-1103
33. Petro TM. ERK-MAP-kinases differentially regulate expression of IL-23 p19 compared with p40 and IFNbeta in Theiler's virus-infected RAW264.7 cells. Immunol Lett 2005; 97:47-53.
34. Bhat NR, Feinstein DL, Shen O, Bhat AN. p38 MAPK-mediated transcriptional activation of inducible nitric-oxide synthase in glial cells. Roles of nuclear factors, nuclear factor kappaB, cAMP response element-binding protein, CCAAT/enhancer-binding protein-beta, and activating transcription factor-2. J Biol Chem 2002; 277:29584-29592
35. Patel DN, King CA, Bailey SR, Holt JW, Venkatachalam K, Agrawal A, et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NFkappaB and C/EBPbeta activation. J Biol Chem 2007; 282:27229-27238 (Pubitemid 47501976)
36. MAPK pathway. Int J Oncol 2007; 31:441-449
37. Hao F, Tan M, Xu X, Han J, Miller DD, Tigyi G, et al. Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA (1), p42 and p38alpha. Biochim Biophys Acta 2007; 1771:883-892
38. Kalari S, Zhao Y, Spannhake EW, Berdyshev EV, Natarajan V. Role of acylglycerol kinase in LPA-induced IL-8 secretion and transactivation of epidermal growth factor-receptor in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2009; 296:328-336
39. Tan KS, Nackley AG, Satterfield K, Maixner W, Diatchenkol L, Flood PM. Beta2 adrenergic receptor activation stimulates pro-inflammatory cytokine production in macrophages via PKA- and NFkappaB-independent mechanisms. Cell Signal 2007; 19:251-260 (Pubitemid 46017083)
40. Panne D, Maniatis T, Harrison SC. An atomic model of the interferon-beta enhanceosome. Cells 2007; 129:1111-1123
41. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7:211-217 (Pubitemid 40568680)
42. Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, et al. STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 2003; 197:157-168 (Pubitemid 37485244)
43. Wegenka UM, Lutticken C, Buschmann J, Yuan J, Lottspeich F, Müller-Esterl W, et al. The interleukin- 6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family. Mol Cell Biol 1994; 14:3186-3196 (Pubitemid 24132732)
44. Li Y, Du H, Qin Y, Roberts J, Cummings OW, Yan C. Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res 2007; 67:8494-8503 (Pubitemid 47437423)
45. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999; 98:295-303.
46. Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A. Signal characteristics of G protein-transactivated EGF receptor. EMBO J 1997; 16:7032-7044 (Pubitemid 27520803)
47. Mori K, Kitayama J, Shida D, Yamashita H, Watanabe T, Nagawa H. Lysophosphatidic acid-induced effects in human colon carcinoma DLD1 cells are partially dependent on transactivation of epidermal growth factor receptor. J Surg Res 2006; 132:56-61.
48. Shah BH, Baukal AJ, Shah FB, Catt KJ. Mechanisms of extracellularly regulated kinases 1/2 activation in adrenal glomerulosa cells by lysophosphatidic acid and epidermal growth factor. Mol Endocrinol 2005; 19:2535-2548
49. Umata T, Hirata M, Takahashi T, Ryu F, Shida S, Takahashi Y, et al. A dual signaling cascade that regulates the ectodomain shedding of heparin-binding epidermal growth factor-like growth factor. J Biol Chem 2001; 276:30475-30482 (Pubitemid 37385135)
50. Wang L, Cummings R, Zhao Y, Kazlauskas A, Sham JK, Morris A, et al. Involvement of phospholipase D2 in lysophosphatidate-induced transactivation of platelet-derived growth factor receptor-beta in human bronchial epithelial cells. J Biol Chem 2003; 278:39931-39940 (Pubitemid 37248557)
51. Rosen EM, Nigam SK, Goldberg ID. Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction. J Biol Chem 1994; 127:1783-1787
52. Rubin JS, Bottaro DP, Aaronson SA. Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochim Biophys Acta 1993; 1155:357-371 (Pubitemid 24012300)
53. Yamauchi H, Cristofanilli M, Nakamura S, Hortobagyi GN, Ueno NT. Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol 2009; 6:387-394
54. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J, et al. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem 2006; 281:17492-17500 (Pubitemid 43909557)
55. Masuda A, Nakamura K, Izutsu K, Igarashi K, Ohkawa R, Jona M, et al. Serum autotaxin measurement in haematological makignancies: a promising marker for follicular lymphoma. Br J Haematol 2008; 143:60-70.
56. Ren J, Xiao YJ, Singh LS, Zhao X, Zhao Z, Feng L, et al. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration and invasion of ovarian cancer cells. Cancer Res 2006; 66:3006-3014
57. Sengupta S, Xiao YJ, Xu Y. A novel laminin-induced LPA autocrine loop in the migration of ovarian cancer cells. FASEB J 2003; 17:1570-1572
58. Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, et al. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res 2003; 9:3534-3545 (Pubitemid 37169216)
59. Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 2002; 1582:257-264 (Pubitemid 34634137)
60. Murph MM, Nguyen GH, Radhakrishna H, Mills GB. Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation. Biochim Biophys Acta 2008; 1781:547-557
61. Mills GB, May C, Hill M, Campbell S, Shaw P, Marks A. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest 1990; 86:851-855 (Pubitemid 20327375)
62. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nature reviews 2009; 9:415-428
63. Wang E, Ngalame Y, Panelli MC, Nguyen-Jackson H, Deavers M, Mueller P, et al. Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res 2005; 11:113-122 (Pubitemid 40075785)
64. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, et al. Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One 2009; 4:5583.
65. Yang SY, Lee J, Park CG, Kim S, Hong S, Chung HC, et al. Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin Exp Metastasis 2002; 19:603-608 (Pubitemid 35454570)
66. Black EJ, Clair T, Delrow J, Neiman P, Gillespie DA. Microarray analysis identifies autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun. Oncogene 2004; 23:2357-2366 (Pubitemid 38496791)
67. Song J, Jie C, Polk P, Shridhar R, Clair T, Zhang J, et al. The candidate tumor suppressor CST6 alters the gene expression profile of human breast carcinoma cells: downregulation of the potent mitogenic, motogenic and angiogenic factor autotaxin. Biochem Biophys Res Commun 2006; 340:175-182 (Pubitemid 41827662)
68. Witt AE, Hines LM, Collins NL, Hu Y, Gunawardane RN, Moreira D, et al. Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. J Proteome Res 2006; 5:599-610. (Pubitemid 43364100)
69. Kitayama J, Shida D, Sako A, Ishikawa M, Hama K, Aoki J, et al. Overexpression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res 2004; 6:640-646
70. Horak CE, Mendoza A, Vega-Valle E, Albaugh M, Graff-Cherry C, McDermott WG, et al. Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2. Cancer Res 2007; 67:11751-11759
71. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci USA 2006; 103:9643-9648 (Pubitemid 43955878)
72. van Corven EJ, Groenink A, Jalink K, Eichholtz T, Moolenaar WH. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell 1989; 59:45-54. (Pubitemid 19248557)
73. Jalink K, Eichholtz T, Postma FR, van Corven EJ, Moolenaar WH. Lysophosphatidic acid induces neuronal shape changes via a novel, receptor-mediated signaling pathway: similarity to thrombin action. Cell Growth Differ 1993; 4:247-255
74. Hordijk PL, Verlaan I, van Corven EJ, Moolenaar WH. Protein tyrosine phosphorylation induced by lysophosphatidic acid in Rat-1 fibroblasts. Evidence that phosphorylation of map kinase is mediated by the Gi-p21ras pathway. J Biol Chem 1994; 269:645-651 (Pubitemid 24026708)
75. Kumagai N, Morii N, Fujisawa K, Nemoto Y, Narumiya S. ADP-ribosylation of rho p21 inhibits lysophosphatidic acid-induced protein tyrosine phosphorylation and phosphatidylinositol 3-kinase activation in cultured Swiss 3T3 cells. J Biol Chem 1993; 268:24535-24538
76. ras by G protein-coupled receptor agonists in fibroblasts. Proc Natl Acad Sci USA 1993; 90:1257-1261
77. 2+ signaling pathways. Curr Biol 1998; 8:386-392
78. 12/13 subunits in neuronal cells: induction of neurite retraction. Mol Biol Cell 1999; 10:1851-1857.
79. i-protein-mediated activation of mitogen-activated protein kinase. Biochem J 2000; 352:135-143
80. Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, et al. Lysophospholipid growth factors in the initiation, progression, metastases and management of ovarian cancer. Ann NY Acad Sci 2000; 905:188-208. (Pubitemid 30255418)
81. Kranenburg O, Moolenaar WH. Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists. Oncogene 2001; 20:1540-1546 (Pubitemid 32336841)
82. Van Leeuwen FN, Olivo C, Grivell S, Giepmans BN, Collard JG, Moolenaar WH. Rac activation by lysophosphatidic acid LPA1 receptors through the guanine nucleotide exchange factor Tiam1. J Biol Chem2003; 278:400-406
83. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752
84. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100:8418-8423 (Pubitemid 36842560)
85. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-10874 (Pubitemid 32878711)
86. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007; 8:341-352
87. Gonzalez-Arenas A, Avendano-Vazquez SE, Cabrera- Wrooman A, Tapia-Carrillo D, Larrea F, Garcia- Becerra R, et al. Regulation of LPA receptor function by estrogens. Biochim Biophys Acta 2008; 1783:253-262
88. Seo H, Kim M, Choi Y, Lee CK, Ka H. Analysis of lysophosphatidic acid (LPA) receptor and LPA-induced endometrial prostaglandin-endoperoxide synthase 2 expression in the porcine uterus. Endocrinology 2008; 149:6166-6175
89. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249
90. Nakamoto T, Yasuda K, Yasuhara M, Yoshimura T, Kinoshita T, Nakajima T, et al. Expression of the endothelial cell differentiation gene 7 (EDG-7), a lysophosphatidic acid receptor, in ovarian tumor. J Obstet Gynaecol Res 2005; 31:344-351 (Pubitemid 41192573)
91. Shida D, Watanabe T, Aoki J, Hama K, Kitayama J, Sonoda H, et al. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab Invest 2004; 84:1352-1362 (Pubitemid 40063699)
92. Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, et al. Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem 2004; 92:1115-1140
93. Yamashita H, Kitayama J, Shida D, Ishikawa M, Hama K, Aoki J, et al. Differential expression of lysophosphatidic acid receptor-2 in intestinal and diffuse type gastric cancer. J Surg Oncol 2006; 93:30-35 (Pubitemid 43038423)
94. 2 receptor mediates mitogenic signals in human colon cancer cells. Am J Physiol Cell Physiol 2005; 289:2-11.
95. Murph M, Mills GB. Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Rev Mol Med 2007; 9:1-18. (Pubitemid 47617558)
96. Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E, Kon J, et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Phar-macol 2003; 64:994-1005. (Pubitemid 37153068)
97. Fischer DJ, Nusser N, Virag T, Yokoyama K, Wang D, Baker DL, et al. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol 2001; 60:776-784 (Pubitemid 32900260)
98. Heise CE, Santos WL, Schreihofer AM, Heasley BH, Mukhin YV, Macdonald TL, et al. Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol 2001; 60:1173-1180
99. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci USA 2006; 103:9643-9648 (Pubitemid 43955878)
100. Stadler CR, Knyazev P, Bange J, Ullrich A. FGFR4 GLY388 isotype suppresses motility of MDA-MB- 231 breast cancer cells by EDG-2 gene repression. Cell Signal 2006; 18:783-794 (Pubitemid 43208932)
101. Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, et al. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res 2006; 66:2740-2748
102. Jiang G, Xu Y, Fujiwara Y, Tsukahara T, Tsukahara R, Gajewiak J, et al. α-Substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. ChemMedChem 2007; 2:679-690
103. i-coupled GPCR. Assay Drug Dev Technol 2008; 6:327-337
104. Marx MH, Wiley RA, Satchell DG, Maguire MH. Darmstoff analogues 3. Actions of choline esters of acetal phosphatidic acids on visceral smooth muscle. J Med Chem 1989; 32:1319-1322
105. 1A receptors in rat brain sections. Br J Pharmacol 2006; 147:596-606.
106. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion and angiogenesis in multiple tumor lineages. Cancer Cell 2006; 9:225-238 (Pubitemid 43357948)
107. Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 2008; 1781:513-518
108. Federico L, Pamuklar Z, Smyth SS, Morris AJ. Therapeutic potential of autotaxin/lysophospholipase D inhibitors. Curr Drug Targets 2008; 9:698-708.
109. Xu Y, Jiang G, Tsukahara R, Fujiwara Y, Tigyi G, Prestwich GD. Phosphonothioate and fluoromethylene phosphonate analogues of cyclic phosphatidic acid: Novel antagonists of lysophosphatidic acid receptors. J Med Chem 2006; 49:5309-5315 (Pubitemid 44262034)
110. Baker DL, Fujiwara Y, Pigg KR, Tsukahara R, Kobayashi S, Murofushi H, et al. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J Biol Chem 2006; 281:22786-22793 (Pubitemid 44242307)
111. Clair T, Koh E, Ptaszynska M, Bandle RW, Liotta LA, Schiffmann E, et al. L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin. Lipids Health Dis 2005; 4:5. (Pubitemid 40594710)
112. Cui P, McCalmont WF, Tomsig JL, Lynch KR, Macdonald TL. α- and β-substituted phosphonate analogs of LPA as autotaxin inhibitors. Bioorg Med Chem 2008; 16:2212-2225
113. Cui P, Tomsig JL, McCalmont WF, Lee S, Becker CJ, Lynch KR, et al. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors. Bioorg Med Chem Lett 2007; 17:1634-1640 (Pubitemid 46274360)
114. Gududuru V, Zeng K, Tsukahara R, Makarova N, Fujiwara Y, Pigg KR, et al. Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors. Bioorg Med Chem Lett 2006; 16:451-456 (Pubitemid 41680645)
115. Durgam GG, Virag T, Walker MD, Tsukahara R, Yasuda S, Liliom K, et al. Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. J Med Chem 2005; 48:4919-4930 (Pubitemid 41033134)
116. Saunders LP, Ouellette A, Bandle R, Chang WC, Zhou H, Misra RN, et al. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Mol Cancer Ther 2008; 7:3352-3362